Anova supports the standardization and automation of industry sponsored clinical trials, compassionate use programs and investigator-initiated trials. We accelerate and reduce the cost of clinical development.
The AnovaOS™ technology platform provides an integrated research network that includes 15k sponsors, 130k active studies, 15k investigational products, 40k research sites, and 100k investigators. We bring the world’s clinical research environment into a single integrated network to streamline the conduct of research.
We accelerate development of complex treatments for cardiology, immunology, infectious disease, oncology and rare disease.
AnovaOS™ supports biopharmaceutical companies (and partner CROs), academic sponsors, and physician-sponsors design, develop, implement and manage the conduct of clinical trials and compassionate use programs. A first-of-a-kind technology focused on accelerating and reducing the cost of clinical development
Design and share your study, find and connect with sites and physicians, match patients to your studies, capture your study and network credentials/essential documents, submit your studies for IRB and regulatory approval, activate and enrol patients just-in-time, collect and manage quality data.
With AnovaOS™ we help patients access investigational treatments wherever they receive care, streamlining recruitment of rare populations, and realizing the promise of precision medicine.
Design and collaborate on your study, undertake study feasibility and access patients across your research network. Structure your protocol for operational efficiency, and standardized data capture across development pathways.
Find and connect with qualified sites and physicians, undertake site feasibility and document site qualification using a comprehensive profile listing all research interests, regulatory credentials and operational capabilities.
Capture a complete set of essential documents and maintain a single regulatory binder for all studies. Seamlessly share study, site and/or physician credentials with regulatory agencies and IRBs.
Patients matched to any study or investigational product in development allows rapid enrolment for highly targeted or rare patient populations. Patient disease registry and classification of inclusion/exclusion criteria used to match eligible patients rather than screen potential patients. Just-in-time application for clinical trials or compassionate use enabled for all sponsors, all studies, all investigational products, and for all physicians, increasing utility of precision medicine and access to targeted treatments.
Activate a site and enroll a patient in 5 working days using master contract and fee schedule, with streamlined regulatory compliance.
Integrated data capture and clinical evidence generation using a standardized protocol representation model (PRM) to enable a learning system across products and indications. The AnovaOS™ architecture enables integration of preferred third-party electronic data capture (EDC) platforms.
“Anova’s forward-thinking approach to Expanded Access has brought Celularity investigational products to cancer and COVID-19 patients in need while generating data that has directly impacted our traditional development efforts.”
“Anova and ERC crafted an ethical Right-to-Try program that has helped patients with brain tumors and generated survival data that has became integral to our regulatory submissions. When we secure marketing approval it will be, in part, due to our partnership with Anova.”
“Anova’s deep regulatory and technical expertise has helped our company navigate conflicts that can (and do) arise with traditional CRO partners. Ethical research that complies with regulatory requirements is a foundation of our work. On multiple occasions, Anova has recommended a path that has been validated by regulators to be the best approach for our company and our products for patients with herpes and COVID-19.”
